Samsung reported to be in in talks to buy Biogen for $42 billion...

Thursday, 30 December 2021, 12:16 pm

Who would have tought there would be multi-billion dollar takeover shenanigans during a short, typically quiet holiday week.

The latest tale doing the rounds is about Samsung holding talks about takeover of Biogen, the US-listed biotechnology company that is developing a drug for Alhzeimer's.

The Korean Economic Daily, citing unnamed investment banking sources, claimed that that the deal could value Biogen at $42 billion. That represents about a 20pc premium from Biogen’s current market cap of about $35 billion...


Register for free to see rest of this article and all public articles from Betaville

Login / Register

[Disclaimer - the information on Betaville does not consitute any form of investment recommendation and is not intended to be relied upon by readers in making, or refraining from, any investment decisions].

Login to join the conversation